Her view is that quicker loss on retatrutide doesn't automatically mean improved metabolic health. It's a short opinion post with no new data behind it.
Recap by typeshit. Post by @anacapozzoli on Instagram.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
A short Philstar Life item on PIONEER 8, a trial of oral semaglutide. The material gives only the title, so tap through for the details.
She points out one trial enrolled people with diabetes and the other excluded them, so the results aren't a head to head match.
Researchers built a topology-guided add-on to AlphaFold3 aimed at the threaded tail that trips up lasso peptide structure prediction.
Lilly reports all three doses met their goals at 80 weeks, with about 11% quitting on 12 mg and 13% reporting dysesthesia. Shares rose about 1% premarket.
Polish public radio covers a new weight-loss medication being talked about as a successor to Ozempic. Details are thin beyond the headline.
Loading…